Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	165
Posts	20598
Boards Moderated	1
Alias Born	11/28/2003

oneinamillion

Re: oneinamillion post# 1360

Tuesday, 01/13/2004 12:22:34 AM

Tuesday, January 13, 2004 12:22:34 AM

BIPH RESEARCH AND DETAIL PAGE-rev #21 -1/13/04

Current Issue: Wow! Over 9 pages long now! Oldtimers stick to current issue highlights for quick update.

January 12th-2004-Institutions continue to buy-Record new 2 year highs(1.65), broke all resistance levels-17.2 mil shares

Biophan to Present at 2004 Medical Device Forum in New York City on January 15-Press Release
http://biz.yahoo.com/bw/040112/125614_1.html

Board Members-Presidental Award Winners-Nobel Laureate,etc. How many here have looked at the Scientific Advisory Board and members listed on the BIPH website as being part of this great company. This is a powerhouse of top scientist in the world.
http://www.biophan.com/scientific.php
Ray Kurzweil was awarded the National Medal of Technology by Pres. Clinton in 1999. He was inducted in 2002 into the National Inventors Hall of Fame, established by the U.S. Patent Office. He received the $500,000 Lemelson-MIT Prize the nation's largest award in invention and innovation.
Herbert Hauptman-Nobel Prize winner and more.
There are several other important physicians listed.
Also:Very Important Contributors
Wilson Greatbach-co-founder of BIPH- was awarded the National Medal of Technology from President Bush, Sr. in 1990. He is the inventor of the pacemaker. And much more.
Ray Damadian-many feel inventor of MRI-was awarded the National Medal of Technology from President Reagan and is in the National Inventors Hall of Fame.

Prior Issue:

This one is packed folks! 1/9/04 activity
January 9th-2004-Institutions recommended to buy-Brokerage America, New Patent,Tops $1,was highest volume ever-10.1 mil

Brokerage America-1/9/04 Senior Analyst recommends Biophan to institutions
http://www.investorshub.com/boards/read_msg.asp?message_id=2101513

German nano fund now has BIPH as number #1 holding
http://www.dac-fonds.de/xist4c/web/H--amp--A-Lux-DAC-NANOTECH-FONDS_id_308_.htm;jsessionid=225314699....

Biophan's Nanotechnology Patents Portfolio Expands- 1/9/04
http://biz.yahoo.com/bw/040109/95223_1.html

2004 Medical Device Forum- on 1/15/04-(OT:Other big speaker SG Cowen-think financing opportunity)
http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=779351&guid=%7B04C5C....

Local Press: Patent powers Biophan's stock- 1/10/04
http://www.democratandchronicle.com/biznews/01105F2TGLV_business.shtml

New charts from boardmembers-$6 price target
http://stockcharts.com/def/servlet/SC.pnf?c=BIPH,P&listNum=

10Q due 1/14 or 1/15-Expect updates

New high since last March 2002= $1.65 on 1/12/04
Closed above $1 at $1.53

Latest Publications:
12/29/03 Analyst calls BIPH in TOP 5 PICKS for 2004
http://ragingbull.lycos.com/mboard/boards.cgi?board=BIPH&read=2314
12/19/03
http://www.smallcapdigest.net/archive/listserv/20031219-1.html
12/23 PR on 12/17 publication both below
http://biz.yahoo.com/bw/031223/235192_1.html
12/17/03
http://www.nhionline.net/products/nanobiotechnews/nbn121703brd.pdf

Authorized Shares: 80mil
10/31 46mil outstanding, 400 shareholders approx.
13 mil est held by insiders;33 million float
Options/warrants/debt=14mil reserved
Financing= The 20mil remaining of the Authorized available
If the stock price rises will not need to use up 20mil.

Patents: 51 filed to be issued: 3 licensed
Patent news:
Biophan's Nanotechnology Patents Portfolio Expands- 1/9/04
http://biz.yahoo.com/bw/040109/95223_1.html

Markets announced:
Pacemaker/ICD's related = $4 billion market place
Stents/Guidewires related = $4 billion market place
Newly announced in December 2003
Artificial limbs = $2 billion market place

New products released:
NanoView Technology-Dec 17th, 2003
http://biz.yahoo.com/bw/031217/175586_1.html

Yes we are a NANO stock:
Picked to be speaker at 2003 NANO Commerce conference:
http://biz.yahoo.com/bw/031209/95418_1.html

Investor websites have us in Key Nanostocks section:
http://investorideas.com/Companies/Nanotechnology/NanotechnologyStockList/NanotechnologyStocks.asp

Stock Section:52 week high $1.65 ;low $.10

Top 13 highest volume days ever:
January 12th-2004-Institutions continue to buy-Record new 2 year highs(1.65), broke all resistance levels-17.2 mil
January 9th-2004-Institutions recommended to buy-Brokerage America, New Patent,Tops $1,highest volume ever-10.1 mil
January 8th-2004-Rally takes a break-2.2 mil
January 7th-2004-Volume/Price breakout continues-4.1 mil
January 5th-2004-Momentum on resistance breakout-8.1 mil
January 2nd-2004-Broke key resistance areas-4.3 mil
December 10th-2003-Nano Conference-2.4 mil
December 9th-2003-Nano Conference-2.1 mil
November 6th-2003-BSX announcement-3.8 mil
November 5th-2003-BSX announcement-8.8 mil
September 29th-2003-2.4 mil
September 26th-2003-2.2 mil
September 25th-2003-BIPH discovered by RB members-2.3 mil

BSX announcement on 11/05/03: http://biz.yahoo.com/bw/031105/55101_1.html

Local Press:
http://www.democratandchronicle.com/biznews/1106T229D0P_BPHAN06_business.shtml

Charts:
Very Bullish-Especially mid to long-term

Independent Chart Analysis-Investor has no interest -See below he was right on target-We broke 50 and ran to 1.65 so far.

http://www.investorshub.com/boards/read_msg.asp?message_id=1865970

Biph RB poster charts:
http://quotes.barchart.com/texpert.asp?sym=biph

http://www.stockta.com/cgi-bin/analysis.pl?symb=BIPH&num1=1&cobrand=&mode=stock

2004 Strategic Initiatives-Dec 19th 2003:
Objectives Call for Further Innovation, Market Expansion and Significant Growth

"We are enthusiastic about our early successes and the milestones we have achieved to date. Most importantly, Biophan looks forward to substantial growth in revenues, earnings and, ultimately, in shareholder value."

http://biz.yahoo.com/bw/031219/195421_1.html

Conferences:

Jan 15th 2004-2004 Medical Device Forum
http://cbs.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=779351&guid=%7B04C5C....

Jan 21st 2004-Investor Council-Medical Device Makers
http://www.wallstreetadvisor.com/council/index.php

Feb 13th-14th-SCMR Conference
http://www.scmr.org

Feb 24th-25th-Investment in Innovation Conference 2004
http://www.medtechinsight.com/pastattendees.html

March 25th-30th-SIR Conference
http://www.sirweb.org/annualMeeting/2004_Exhibitors_Prospectus.pdf

COMPANY PRESENTATIONS:
Companies presentation from website:
I think it is very good. Sums it up well.

Latest 12/03:
http://www.biophan.com/presentations/BIPH120403_files/frame.htm

Prior to 12/03

http://www.biophan.com/presentations/MWPPpresentationasof072203_files/frame.htm

Audio presentation from 11/21 Conference:
Click on the link below and after the conference begins you need to skip through the opening comment. The BIOPHAN piece is from about the 29 minute to the 38 minute of the 1 hour presentation.

http://www.informedinvestors.com/iif_forums/client_capsule.cfm?companyID=1101

Key Notes from Current SB/424b filing:

Page 8:
"On September 25, 2003, we entered into a development agreement with Boston Scientific Corp., a biomedical device company. We are also developing relationships with other potential partners".

We have identified a core group of potential customers/development partners for our technology and continue to meet with these companies on a regular basis. We are obligated by confidentiality and nondisclosure agreements with the companies we are speaking with concerning potential relationships. This is from Page 21.

Also, more on BSX and others on page 21.
Consistent with our business strategy, on September 25, 2003, we entered into a development agreement with Boston Scientific Corp., a medical device manufacturer, to develop MRI capability for one of their products. The terms of this development agreement are confidential. Additionally, our negotiations with other biomedical device manufacturers and our evaluation of their proposals is continuing.

Our goal is to enter into a development arrangement with several or more of these entities whereby each entity would provide financial and research support to further the commercialization of our technologies. In addition to seeking development arrangements with potential partners, we will continue to

Page 22

expand our technology portfolio by seeking to acquire complementary technologies through licensing arrangements with other third parties. Key members of our management team have and will continue to attend and present technical papers at industry trade conferences and to leaders in the pacing and medical device arena.

More deals are going to be signed on Page 27

All of these potential business relationships are being pursued with the interest of funding the remaining development work, supporting necessary clinical trials and approvals, and ultimately resulting in a license for manufactured products with royalties coming to Biophan. Consistent with our business strategy, on September 25, 2003, we entered into a development agreement with Boston Scientific Corp., a medical device manufacturer, to develop MRI capability for one of their products. The nature and terms of this development agreement are confidential. Additionally, our negotiations with other biomedical device manufacturers and our evaluation of their proposals is continuing. This is from page 27.

Page 29-Companies want to license already

"To date, we have received licensing interest in our technology from pacemaker, guidewire and neurological device companies, but we have not yet entered into any licenses for the technology".

2 Big developmental deals on Page 31 and 32

2 different deals to cover a larger group of devices(this opens huge licensing potential)

Biophan has entered into a development agreement with the UB Business Alliance (at the University of Buffalo). The objective of the first phase of this collaboration focused on developing the means to shield implanted medical devices, such as a catheter, from the harmful effects of MRI. The second phase of this collaboration is focusing on improving the shielding technology developed in phase one by optimizing the formulation through the use of a magnetic additive. The technology being developed by this collaboration consists of small carbon materials manufactured in a flexible polymer support. Major activities include development of optimally performing mixtures of carbon and polymer materials and the application of these optimal formulations to medical devices. Under the terms of the agreement for phase one of the collaboration, we paid $23,375 toward the total project cost of $42,994. All aspects and obligations of phase one have been completed and satisfied. Biophan will pay $31,922 toward the total phase two project cost of $50,539 in four equal installments of $7,980.50. The initial amounts were paid August 15, 2003 and October 24, 2003, and subsequent installments are due and payable as follows: January 31, 2004 and a final payment within 30 days of the receipt of the final project report. Phase two of this collaboration is expected to be completed in August of 2004.

Biophan has also entered into agreements with Alfred University. The objective of this collaboration is to develop the means to shield implanted medical devices, such as pacemaker leads, from the harmful effects of MRI and to resolve image artifacts in medical devices such as guidewires, stents, pacing leads and other medical devices. The technology being developed by this collaboration consists of nano-magnetic materials and the processes used to apply these materials as uniform, thin-film coatings. Major activities include the development of optimal nano-magnetic coating formulations, delivery of coated pacemaker leads, the delivery of coated guidewires and

Page 32

other devices suitable for testing, processes for applying these formulations to medical devices, and the testing of these devices in an MRI system. This collaboration also provides Biophan with access to expensive, thin-film coating equipment considered essential to the development of effective nano- magnetic MRI shielding materials. Biophan has paid Alfred University $127,200 to date for these services.

While the objectives of the two collaborations are similar (i.e. the development and evaluation of MRI shielding materials), it should be understood that each collaboration is developing a different technology. The success of these collaborations would provide Biophan with multiple solutions to the MRI safety problem. Biophan considers this to be very important, since the MRI shielding requirements differ by product type, and having multiple solutions would enable us to apply our technologies to a broader range of products.

PG 32-Why BIPH will continue to have an edge

The inventor of the nanomagnetic shield technology, Dr. Xingwu Wang, at Alfred University, New York, has applied for an additional nine US patent applications covering further improvements extensions to that technology; these will also be licensed exclusively to Biophan for medical markets.

Page 34 -More on deals being work on right now.

"We are currently having discussions, under confidentiality agreements, with manufacturers of primary device components such as pacemaker leads, as well as manufacturers of complete systems, concerning their use of this technology. Ongoing research, test, and evaluation activities in nanomagnetic shielding are being done internally, and in conjunction with Dr. Wang (the inventor of the technology) at Alfred University, and Dr. Chung at the University of Buffalo".

Page 40-42-Talks about Potential Partners-J&J etc.
or licensee. They could become competitors. But BIPH feels they are in a very advanced phase and have the best solution.

We anticipate that we will license our technology to one or more development partners who would be responsible to develop commercial products, obtain necessary approvals, manufacture, market and distribute the products.

Page 41

We expect our search for development partners will be global, although our current efforts are focused on the U.S. operations of certain multi-national companies. However, we can not presently identify or predict the precise target markets, distribution methods or other marketing efforts of our potential development partners.

Competition

There are a number of major companies engaged in the development of medical devices some of which may be investigating MRI safe options. However, to the best of our knowledge none of these companies, nor other companies that serve as their suppliers, have successfully developed technology enabling implantable medical devices to be operated in the presence of MRI equipment. We believe that in order to commercialize our technologies we will have to enter into a development or licensing agreement with one or more of the companies engaged in the development of medical devices.

Currently, the major providers of active medical devices contraindicated for MRI include the following companies:

Medtronic Incorporated is a leading manufacturer of cardiac rhythm management, cardiovascular and other medical devices. The company has a dominant position in cardiac pacemakers, is the leading manufacturer of implantable cardiac defibrillators, and is a major player in most other device markets in which it competes.

Guidant Corporation is also a leading manufacturer of cardiac rhythm management devices such as cardiac pacemakers, implantable cardiac defibrillators, interventional cardiology devices (including coronary stents), and other cardiac and vascular surgery devices and instruments.

St. Jude Medical, Inc. is a global developer, manufacturer, and distributor of medical device products for cardiac rhythm management, cardiology and vascular access. Other products include mechanical and tissue heart valves and vascular closure devices.

Boston Scientific Corporation is the world's largest medical device company dedicated to less-invasive therapies. The Company's products and technologies are designed to improve surgical procedures and improve patient response, and involve a range of interventional tools and procedures.

Johnson & Johnson is the world's largest healthcare company. In addition to OTC and home healthcare products, they provide a wide variety of pharmaceutical, diagnostic, and surgical products.

We do not consider the above companies to be direct competitors, although they may possibly be developing MRI safe solutions for their own product lines. Rather, they may have interest in adopting one or more of our

Page 42

technologies into their products. Various first and second tier suppliers to these companies may be directly affected by either the photonic or shielding technologies we plan to commercialize, and since to the best of our knowledge none of them has satisfactory solutions to MRI issues, they are potential additional or alternative prospects for commercializing our technology.

Manufacturing and Component Strategy

We are developing technology for MRI safety and image compatibility which will be licensed to leading biomedical device manufacturers. We do not plan to manufacture any product or component on our own. We may provide critical components and coating devices sourced from third parties and resold to our customers.

Financing:
Current:
Spectrum Agreement. Good till July 11,2005. Value $3.0mil.(Certain clauses allow up to $10mil). BIPH can sell shares at 80% of prior 3 day average daily volume. So, if 50 cents. Spectrum pays 40 cents. That's why we have had a little pressure on slow days from the financing company(They make money if they sell as they receive financing shares). 8,960,000 registered(3,325,757issued at 11/21). Balance remaining 5,634,243. The issued shares only got the company 14-15 cents. But right now the company can get over $1 as of 1/12/04. We hope that difference only gets better and thus less shares will need to be issued. Company very good on not abusing issued shares and keeping focused on business plan.

New:
11/21 Finalized new financing agreement put together when stock was trading between 15-25 cents area. SBI agreement.
It's valued at 2.9 mil for operating purposes. I believe this is truly a back up plan. With the recent rise I am almost sure of it in 2004.

It has 6 tranches and BIPH has no obligation to sell to SBI any shares but once they start a tranche they must complete it. They are 2mil at .15, 2mil at .20, 2mil at .25, 2 mil at .30, 2mil at .35, 1mil at .40 for an average of .264.

Not bad based on where they were trading and they needed a back up plan in case things took longer than planned or the markets reaction to the stock was not immediate. I think this agreement may never be completed and that at worst the terms will be upgraded. IMO. The market has reacted favorably to BSX news and has the stock trading between .29 and $1.65.

Sleeper Products:
The other sleeper products they could release at
anytime is talked in detail about in the filing. Much is made about what they think they can get to the market fastest(MRI sheilding/coating of existing medical devices). But look closely.

"Our current research efforts are focused on demonstrating the feasibility of our coating and filtering solutions that we intend to license to medical device manufacturers. Initial tests of these solutions have been promising enabling us to have discussions with several companies regarding potential development arrangements." BSX is one.

Now for the sleepers:
1. "The fiber-optic lead has been tested in an MRI machine and does not heat up as do existing catheters that contain metal wires. We are exploring the use of this technology with third parties, under license, for use in deep brain stimulation applications, such as treating movement related disorders like Parkinson's disease and epilepsy. We have also received OEM licensing interest from several companies wishing to use the fiber-optic lead to power intraluminal coils. We are anticipating one or more R&D contracts to help finance the development of this product that is based upon Biophan's photonic technology platform."

2.We subcontracted the development and testing of a photonic temporary pacemaker device to Greatbatch Enterprises. This phase of the development work has been completed. The photonic temporary pacemaker is intended as a backup for patients who need MRI diagnosis but who already have an implanted pacemaker or implantable cardioverter defibrillator (ICD).

3.The HIV business:
During 2001, we entered into a Commercial Research and Development Agreement (CRADA) with the National Institutes of Health and the University of Rochester Cancer Center, wherein these organizations conduct research and development associated with the antisense technology. This allowed us to put our full resources into the development of the MRI safety improvements to biomedical products. In 2002, we decided to discontinue research and development of the HIV antisense technology and the CRADA was terminated. While the technology holds promise and has issued patents, we feel our most promising opportunity is in the MRI safe solutions we have developed and we intend to focus our research and development activities on that technology. We may sell the HIV antisense patents if an appropriate buyer can be identified.

4. The FDA has already approved for sale intra-luminal imaging catheters that utilize electrical leads to provide power to the microcoil and to carry received signals back to the MRI system. Biophan is in discussions with one company that has such a product, and we believe that our photonic technology will permit improvements in performance due to its inherent immunity to electromagnetic noise created by the MRI environment. We are under a non- disclosure agreement with this other company and it is our expectation that if we move forward to develop a photonic intraluminal imaging catheter, they will be responsible for regulatory approval and for marketing and sale of the product.

5. NanoView Technology-Announced Dec. 2003
"This technology may have a substantial impact on magnetic resonance imaging (MRI) and other diagnostic imaging applications. NanoView could significantly improve the quality and effectiveness of these procedures. Consistent with its business strategy, Biophan is offering its NanoView technologies to organizations with established distribution and marketing channels. Biophan has had preliminary discussions with several organizations and there has been interest expressed in the technology and the benefits it provides. As such, we expect that NanoView technology may be a tremendous catalyst for Biophan's future growth," Weiner stated

Disclaimer:
I will be editing the Research Page-Excuse me
while I get it together. It will be a work in progress and I will take info from other posters in addition to my research unless you specifically tell me not to add it on the post. Everyone here deserves credit so I will not be posting credits-We are here to make money not reputations. The information posted here should be confirmed through your own DD and should not be the sole basis for your investment. Stocks in the OTCBB carry heavy risk(if you trade pennies you know what they are).

BOARD OPTIMIST

Keep Last Read

Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community